US High Growth Tech Stocks to Watch

Simply Wall St.
Yesterday

The United States market has experienced a notable upswing, rising 7.1% over the last week and climbing 7.7% in the past year, with earnings forecasted to grow by 14% annually. In this context of growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to evolving market trends.

Top 10 High Growth Tech Companies In The United States

Name Revenue Growth Earnings Growth Growth Rating
Super Micro Computer 20.27% 29.79% ★★★★★★
Alkami Technology 20.46% 85.16% ★★★★★★
Travere Therapeutics 28.65% 66.06% ★★★★★★
TG Therapeutics 26.06% 37.39% ★★★★★★
Arcutis Biotherapeutics 26.11% 58.46% ★★★★★★
Clene 62.08% 64.01% ★★★★★★
Alnylam Pharmaceuticals 23.08% 58.85% ★★★★★★
AVITA Medical 27.81% 55.17% ★★★★★★
Lumentum Holdings 21.34% 120.49% ★★★★★★
Ascendis Pharma 32.75% 59.64% ★★★★★★

Click here to see the full list of 233 stocks from our US High Growth Tech and AI Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Exact Sciences

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Exact Sciences Corporation develops and markets cancer screening and diagnostic test products globally, with a market cap of approximately $8.44 billion.

Operations: The company generates revenue primarily from its biotechnology segment, totaling approximately $2.76 billion. Its focus on cancer screening and diagnostic tests positions it within the healthcare sector, targeting both domestic and international markets.

Exact Sciences is making significant strides in the high-growth tech sector, particularly with its recent advancements in cancer diagnostics. The launch of Oncodetect, a test for detecting molecular residual disease across multiple solid tumors, showcases their commitment to innovation; this test enhances treatment decisions and monitoring with its ability to detect one ctDNA molecule among 20,000 cfDNA molecules. With an R&D expense ratio that has consistently been above industry average at 15% of revenue, Exact Sciences is not just expanding its product line but also ensuring these innovations reach a broad audience through strategic Medicare collaborations and robust clinical validations like the Alpha-CORRECT study. This approach not only secures their position in precision medicine but also aligns with broader healthcare trends towards personalized care solutions.

  • Get an in-depth perspective on Exact Sciences' performance by reading our health report here.
  • Review our historical performance report to gain insights into Exact Sciences''s past performance.

NasdaqCM:EXAS Revenue and Expenses Breakdown as at Apr 2025

DigitalOcean Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: DigitalOcean Holdings, Inc. operates a cloud computing platform serving customers in North America, Europe, Asia, and other international markets with a market cap of $2.83 billion.

Operations: DigitalOcean generates revenue primarily from its Internet Software & Services segment, which reported $780.62 million. The company focuses on providing cloud computing solutions across various global markets.

DigitalOcean Holdings, Inc. (DOCN) has demonstrated robust growth and innovation in the tech sector, particularly with its recent product enhancements and strategic acquisitions. The company reported a significant 335.3% earnings growth over the past year, driven by smart expansions like the acquisition of Cloudways and Paperspace, which bolstered both revenue streams and technological capabilities. Its R&D spending is strategically aligned with its growth trajectory, ensuring continual innovation in cloud infrastructure services. With an anticipated annual revenue increase of 12.3% and earnings expected to rise by 23% per year, DOCN is effectively leveraging technological advancements to enhance scalability and performance for its clients. Recent launches like DigitalOcean Managed Caching for Valkey highlight its commitment to high-performance solutions that cater to dynamic market needs while maintaining competitive pricing structures.

  • Unlock comprehensive insights into our analysis of DigitalOcean Holdings stock in this health report.
  • Gain insights into DigitalOcean Holdings' historical performance by reviewing our past performance report.

NYSE:DOCN Revenue and Expenses Breakdown as at Apr 2025

Grindr

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Grindr Inc. operates a social networking and dating application catering to the LGBTQ communities globally, with a market cap of approximately $4.39 billion.

Operations: The company generates revenue primarily through its role as an Internet Information Provider, with reported figures of $344.64 million.

Grindr's strategic expansions and innovative features, such as the recent rollout of "Right Now" in major cities worldwide, underscore its commitment to enhancing real-time user engagement. Despite being unprofitable with a significant net loss of $131 million in 2024, the company has managed to increase its revenue by 17.4% annually, outpacing the US market average of 8.2%. This growth is supported by a robust R&D focus which aligns with projected profitability within three years and an expected annual earnings increase of 46.18%. Moreover, Grindr's proactive approach in repurchasing $500 million worth of its stock signals confidence in its financial strategy and future market position.

  • Dive into the specifics of Grindr here with our thorough health report.
  • Evaluate Grindr's historical performance by accessing our past performance report.

NYSE:GRND Revenue and Expenses Breakdown as at Apr 2025

Summing It All Up

  • Dive into all 233 of the US High Growth Tech and AI Stocks we have identified here.
  • Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
  • Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Want To Explore Some Alternatives?

  • Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
  • Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
  • Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:EXAS NYSE:DOCN and NYSE:GRND.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10